MOTS-c

Typical use cases

Dosing guidelines

Titration

Community protocols typically describe starting at a lower weekly dose to gauge tolerance, then increasing dosing frequency (e.g., to 2-3 times weekly) toward a 5-10 mg/week range; some run intermittent schedules or fixed 4-8 week cycles. These are reported practices, not recommendations.

Reconstitution

Lyophilized powder is reconstituted with bacteriostatic water added slowly down the vial wall and swirled gently (never shaken); e.g., 2 mL into a 10 mg vial yields 5 mg/mL, so 0.2 mL = 1 mg.

Injection sites

Subcutaneous injection, typically into the abdominal fat pad, outer thigh, or back of the upper arm, using a 29-31 gauge insulin syringe; rotating sites is commonly described.

Storage & handling

Store lyophilized powder frozen (around -20C) for long-term; keep reconstituted solution refrigerated at 2-8C and use within about 4 weeks. Protect from light and avoid repeated freeze-thaw.

Side effects

• Injection-site reaction (redness, swelling, painless bumps) Mild · Common
• Fatigue, often in the first week Mild · Common
• Headache Mild · Uncommon
• Mild gastrointestinal upset (nausea, stomach discomfort) Mild · Uncommon
• Flushing Mild · Uncommon
• Palpitations or increased heart rate Moderate · Rare

Research summary

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial MT-RNR1 (12S rRNA) gene, first described in 2015 by Lee and colleagues at USC. The preclinical evidence base is the strongest: in mice it activates AMPK, increases glucose uptake and fatty-acid oxidation in skeletal muscle, reduces diet-induced obesity and insulin resistance, and has been reported to improve age-related insulin sensitivity within roughly a week. Under metabolic stress it translocates to the nucleus in an AMPK-dependent manner and engages stress-response programs (e.g., NRF2/antioxidant-response genes), and skeletal-muscle expression rises after exercise, underpinning its "exercise mimetic" framing. Human data remain observational and limited: circulating MOTS-c correlates with exercise, age, and some metabolic markers, but associations (e.g., with BMI) are inconsistent across cohorts. Direct human therapeutic evidence is sparse; the most advanced clinical work involved CB4211, a MOTS-c analog (not the native peptide), whose Phase 1 trial was temporarily paused for persistent injection-site reactions before resuming under a modified protocol and reporting it was generally well tolerated. Key limitations include unresolved questions about how the peptide enters cells, the absence of published human pharmacokinetics for the native peptide, and no approved clinical application. Overall the compound is best interpreted as physiology/biomarker research rather than an established therapy.

Key references

• https://en.wikipedia.org/wiki/MOTS-c
• https://pmc.ncbi.nlm.nih.gov/articles/PMC4350682/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC9905433/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC6462348/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC8275580/
• https://www.usada.org/spirit-of-sport/what-is-mots-c-peptide/

Related compounds